Hanseatic Management Services Inc. trimmed its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 1.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,506 shares of the medical research company’s stock after selling 70 shares during the period. Edwards Lifesciences comprises 1.2% of Hanseatic Management Services Inc.’s holdings, making the stock its 13th largest position. Hanseatic Management Services Inc.’s holdings in Edwards Lifesciences were worth $1,202,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. FTB Advisors Inc. bought a new position in Edwards Lifesciences in the 1st quarter valued at about $25,000. Evolution Wealth Advisors LLC bought a new position in shares of Edwards Lifesciences during the second quarter worth approximately $29,000. Field & Main Bank bought a new position in shares of Edwards Lifesciences during the first quarter worth approximately $34,000. WP Advisors LLC bought a new position in shares of Edwards Lifesciences during the first quarter worth approximately $35,000. Finally, Parkside Financial Bank & Trust increased its holdings in shares of Edwards Lifesciences by 61.4% during the first quarter. Parkside Financial Bank & Trust now owns 247 shares of the medical research company’s stock worth $47,000 after purchasing an additional 94 shares during the period. Institutional investors own 82.16% of the company’s stock.
In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 4,188 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $176.17, for a total value of $737,799.96. Following the sale, the vice president now owns 44,598 shares in the company, valued at $7,856,829.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 300 shares of the firm’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $178.54, for a total transaction of $53,562.00. Following the completion of the sale, the vice president now owns 19,415 shares in the company, valued at approximately $3,466,354.10. The disclosure for this sale can be found here. Insiders sold 140,975 shares of company stock worth $26,181,339 in the last 90 days. Company insiders own 1.63% of the company’s stock.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.05. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The firm’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same period last year, the firm posted $1.24 earnings per share. Sell-side analysts expect that Edwards Lifesciences Corp will post 5.34 earnings per share for the current fiscal year.
Several brokerages have recently commented on EW. Jefferies Financial Group raised their target price on shares of Texas Instruments from $137.00 to $170.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Zacks Investment Research cut shares of Hallmark Financial Services from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Barclays cut shares of FirstCash from an “overweight” rating to an “equal weight” rating in a report on Wednesday, July 24th. They noted that the move was a valuation call. Stifel Nicolaus cut shares of Owens Corning from a “buy” rating to a “hold” rating and set a $52.45 target price on the stock. in a report on Wednesday, April 24th. Finally, Deutsche Bank raised their target price on shares of Texas Instruments from $100.00 to $110.00 and gave the stock a “hold” rating in a report on Wednesday, April 24th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the company. Edwards Lifesciences presently has a consensus rating of “Buy” and a consensus target price of $204.74.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Recommended Story: Preferred Stock
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.